Navigation Links
Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board

SAN DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that its Board of Directors has elected Paulo F. Costa as Chairman of the Board, effective immediately.

Mr. Costa was formerly President and Chief Executive Officer of Novartis U.S. Corporation, where he held several other executive positions, including Head of the Americas and President and Chief Executive Officer of Novartis Pharmaceutical Corporation. Prior to joining Novartis, Mr. Costa worked at Johnson & Johnson for 30 years, where he served as President of Janssen Pharmaceutica, Executive Vice President, Global Franchise Development, and was a member of Johnson & Johnson's Group Operating Committee. Mr. Costa has held various sales and marketing positions and has more than 20 years of general management experience, having launched 10 pharmaceutical products in various therapeutic areas in the U.S. market. He was elected to Amylin's Board at the Company's Annual Meeting of Stockholders on May 27, 2009.

"Our unanimous decision to name Paulo as Chairman reflects the Board's confidence in his leadership abilities," said James R. Gavin III, M.D., Ph.D., Director and Chair of Amylin's Corporate Governance Committee. "Paulo brings a fresh perspective to all aspects of Amylin's business at this important time for the Company, and his expertise regarding operational and commercial activities will be invaluable as we prepare for the launch of exenatide once weekly. We continue to position Amylin to compete and win in the diabetes and obesity markets. On behalf of the entire Board of Directors, we look forward to working with Paulo in his new leadership role."

"It is with great honor and pleasure that I accept the position of Amylin's Chairman," said Mr. Costa. "I am excited about working closely with my fellow Directors to help Amylin successfully discover, develop and commercialize innovative medicines to improve the lives of patients with diabetes. By doing this well, we will deliver superior value to our shareholders."

Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. The Company's actual results could differ materially from those discussed due to a number of risks and uncertainties, including that our clinical trials may not start when planned and/or confirm previous results; our preclinical studies may not be predictive; our product candidates may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process. These and additional risks and uncertainties are described more fully in the Company's most recently filed SEC documents, including its Form 10-Q. Amylin undertakes no duty to update these forward-looking statements.

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amylin Pharmaceuticals to Webcast Second Quarter Results
2. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
3. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
4. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
5. Amylin Announces Preliminary Tabulation of Annual Meeting Results
6. Amylin Responds to Eastbourne Letter
7. Amylin Comments on RiskMetrics Report
8. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
9. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
10. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
11. Amylin Issues Statement in Response to Carl Icahn
Post Your Comments:
(Date:6/27/2016)... /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... shareholders, Clean Technology Fund I, LP and Clean Technology ... based venture capital funds which together hold approximately 59% ... diluted, as converted basis), that they have entered into ... holdings in Biorem to TUS Holdings Co. Ltd. ("TUS") ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former ... of the University of North Carolina Kenan-Flagler Business School effective June ... UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes and ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):